AMArchana Mukherjee

Archana Mukherjee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Archana Mukherjee has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antibody Fragment-Based TROP-2 Targeting: Preclinical Evaluation of of ¹⁷⁷Lu-Sacituzumab F(ab’)₂ for Triple-Negative Breast Cancer

    by Rohit Sharma, Archana Mukherjee

    Background Trophoblast cell-surface antigen 2 (TROP-2) is highly expressed in triple-negative breast cancer (TNBC) and several other solid tumors, making it an attractive target for radiotheranostic applications. This study aimed to develop and evaluate a 177 Lu-labeled F(ab')₂ fragment of Sacituzumab as a TROP-2–targeted radiotheranostic agent.F(ab')₂ fragments of Sacituzumab were generated by pepsin digestion and conjugated with p-SCN-Bn-CHX-A″-DTPA, followed by radiolabeling with 177 Lu. The resulting radioconjugate was characterized using chromatographic techniques. In vitro cell-binding and saturation-binding studies were performed in several cell lines to assess specificity and binding affinity. In vivo biodistribution studies were conducted in T47D- and SK-OV-3 tumor-bearing nude mouse models. Results F(ab')₂-Sacituzumab fragments were obtained with an approximate yield of 55% and were successfully conjugated with CHX-A″-DTPA. Radiolabeling with 177 Lu achieved a radiochemical purity of > 98% after purification. In vitro studies demonstrated specific uptake in T47D, MDA-MB-231, and SK-OV-3 cells, while saturation-binding assays confirmed high-affinity binding to TROP-2–expressing cells. Biodistribution studies showed substantial tumor accumulation in both tumor xenografts, with predominant renal clearance and minimal uptake in non-target tissues. High tumor-to-background ratios were observed, indicating favorable pharmacokinetic behavior. Conclusions [ 177 Lu]Lu-DTPA-F(ab')₂-Sacituzumab demonstrated strong and selective targeting of TROP-2–expressing tumors, favorable biodistribution, and efficient tumor localization. These findings support its potential as a promising radiotheranostic agent for TNBC and other TROP-2–overexpressing malignancies and warrant further translational and clinical evaluation.

  • Advancing infection imaging: A one-⁠step radioformulation strategy using antimicrobial peptide cold kit

    by Anoushka Sachdeva, Jyotsna Bhatt Mitra, Bibekananda Pati, Anuj Kumar, Yogita Shete, Swati Bagul, Anupam Bandyopadhyay, Archana Mukherjee

  • Open Access

    Advancing Infection Imaging: A One-⁠Step Radioformulation Strategy Using Antimicrobial Peptide Cold Kit

    by Anoushka Sachdeva, Jyotsna Bhatt Mitra, Bibekananda Pati, Anuj Kumar, Yogita Shete, Swati Bagul, Anupam Bandyopadhyay, Archana Mukherjee

    A B S T R A C TPurposeFor early detection of infections, timely treatment, and to help limit the growing problem of antibiotic resistance, there is a need for sensitive and specific infection imaging agents. Additionally, such formulations should be simple to prepare and cost-effective to support clinical translation. With this objective, an extemporaneous formulation of an infection imaging agent was prepared using a cold kit of Ubiquicidin (UBI) fragment enabling the detection of focal infections through positron emission tomography (PET).MethodsA single-vial kit for the preparation of [68Ga]Ga-UBI (29–41) was developed using in-house synthesized UBI (29–41) peptide conjugated to a suitable chelator for radiolabeling with positron emitter, Gallium-68. Six batches of cold kits were prepared and subjected to quality control evaluation to ensure reproducibility of the radiotracer formulation.ResultsPatient doses of [68Ga]Ga-UBI (29–41) were successfully prepared from the cold kits with high radiochemical purity. The radiolabeled formulation demonstrated stability in both serum and saline. In vitro studies with Staphylococcus aureus and in vivo evaluations through biodistribution and imaging in infection-bearing animal models showed significant uptake of the tracer at the sites of infection.ConclusionsA reliable cold kit formulation of UBI (29–41) was successfully developed, enabling rapid and convenient preparation of [68Ga]Ga-UBI (29–41) in hospital radiopharmacies. The availability of a cold kit for preparing the radioformulation is expected to accelerate multicentric clinical trials and support data generation to confirm the potential of [68Ga]Ga-UBI (29–41) for detecting focal infections using PET.

  • Lipocentric Non-Pore-Forming Membrane Depolarization Underlies the Antibacterial Activity of Ribosomal Protein S30

    by J. Bhatt Mitra, V. K. Sharma, M. Kumar, V. García Sakai, A. Mukherjee

    Ribosomal protein S30 (RS30) exhibits potent antimicrobial activity, yet its precise mechanism of action has remained unresolved. Here, we uncover a fundamentally distinct mechanism by which RS30 kills bacteria through lipocentric, non-pore-forming membrane depolarization. By integrating microbiological assays, thermodynamic measurements, and quasielastic neutron scattering, we demonstrate that RS30 selectively binds anionic, bacterial-mimetic membranes via electrostatic interactions and markedly suppresses lipid lateral diffusion. This restriction of membrane mobility may promote lipid rearrangements that generate transient defects sufficient to collapse the membrane potential without large-scale permeabilization. The striking dissociation between depolarization and lysis implies a lipocentric mechanism centered on modulation of membrane dynamics rather than peptide oligomerization or stable transmembrane pore formation. Importantly, RS30 exhibits negligible cytotoxicity toward mammalian cells, highlighting its exceptional selectivity. These findings identify RS30 as a nonlytic antimicrobial agent and provide a strategic framework for next-generation therapeutics and precision infection-imaging probes.

  • Open Access

    Current Status and Developments in Biodosimetry Research in India

    by Ranjana Pathak, Anjana Goel, Archana Mukherjee

    In the current global scenario, human populations remain increasingly susceptible to radiation exposure due to several contributing factors. These include the expanding use of radiation-based technologies to improve quality of life, the growth of nuclear industries and space research activities, geopolitical tensions among nuclear-armed states, and the persistent threat of nuclear terrorism, all of which collectively elevate the risk of large-scale radiation exposure. Biodosimetry, which relies on the detection of radiation-induced cytogenetic and molecular biomarkers, is a globally recognized scientific approach for early triage and absorbed dose assessment following radiation exposure. In India, the biodosimetry facility at the Bhabha Atomic Research Centre (BARC), Mumbai, has pioneered dose-estimation techniques and remains the country’s nodal reference laboratory responsible for conducting biodosimetry for suspected over-exposed individuals in regulatory, emergency, and other critical situations. To strengthen national preparedness, BARC has launched the Indian Biodosimetry Network (IN-BioDoS) for inter-laboratory comparison (ILC) and capacity building. Six laboratories from different regions of India have been included in this network. Currently, more than ten Indian Universities/research institutes are focusing on radiation biology research, contributing to the development of skilled professionals who can carry forward the nation’s biodosimetry program. Over the past few decades, biodosimetry research has seen notable progress. A comprehensive review of literature sourced from databases such as PubMed, ScienceDirect, and Google Scholar reveals that Indian researchers have made significant contributions to the advancement of biological dosimetry. In this context, the aim of this review is to provide a detailed overview of ionizing radiation exposure sources, dose quantification methods, and the application of biodosimetry from an Indian perspective. Furthermore, the review summarizes two decades of research and development carried out by Indian scientists across thematic areas such as basic research, radiation dose assessment, biodosimetry in radiological emergencies, and ILCs. Recent advances and future perspectives are also briefly discussed.

  • Open Access

    Assessing the radiation-induced bystander effect in radionuclide therapy using targeted radiopharmaceuticals

    by Rohit Sharma, Archana Mukherjee, Poonam Jagasia, Suman Kumar Singh

    Radiation-induced biologic bystander effects (RIBBEs) where non-irradiated cells display radiation like responses are well established in the context of ex


  • Synthesis and Evaluation of [ 177 Lu]Lu-Labeled-NLS-Trastuzumab Conjugate for Targeting of HER2 Positive Metastatic Breast Cancer: Evaluating the Effect on Intracellular Localization

    by Soumi Kolay, V. Kusum Vats, Rohit Sharma, Mohini Guleria, Jeyachitra Amirdhanayagam, Naveen Kumar, Manoj Kumbhakar, Archana Mukherjee, Tapas Das

    [177Lu]-Lu-DOTA-Trastuzumab is currently under clinical evaluation for radioimmunotherapy (RIT) for HER2-positive breast cancer. This study aimed to enhance its internalization by modifying Trastuzumab with a nuclear localization signal (NLS: PKKKRKV). The NLS, bearing a terminal azide group, was synthesized via solid-phase peptide synthesis. DOTA, a chelator for 177Lu, was incorporated at the α-amino group of lysine at the NLS's proline end, allowing UV-vis-based drug-to-antibody ratio (DAR) estimation. Both DOTA-Trastuzumab and DOTA-NLS-Trastuzumab, along with their [177Lu]-Lu-labeled counterparts, were synthesized. In vitro studies in HER2-positive SK-OV-3 and SK-BR-3 cells showed an enhanced internalization of the NLS-modified conjugate. However, ex vivo and in vivo evaluation in SCID mice revealed lower tumor and nontarget organ accumulation for [177Lu]-Lu-DOTA-NLS-Trastuzumab compared to [177Lu]-Lu-DOTA-Trastuzumab, indicating altered biodistribution despite improved cellular uptake.


  • Ubiquicidin derived peptides for infection imaging

    by Anoushka Sachdeva, Jyotsna Bhatt Mitra, Archana Mukherjee


  • Open Access

    Tumor‐Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger‐Chemotherapy in Triple‐Negative Breast Cancer

    by Shishu Kant Suman, Biji Balakrishnan, Madhava B. Mallia, Archana Mukherjee

    This study focuses on developing a tumor‐responsive core‐shell glyconanoparticle formulation targeting galectin‐3 (Gal‐3) in triple‐negative breast cancer (TNBC) for Auger‐chemotherapy. The formulation utilizes citrus pectin dialdehyde (CPDA) to create nanoparticles capable of tumor‐responsive release of the drug Doxorubicin (Dox) for chemotherapy and incorporating the radionuclide, Iodine‐125 for Auger therapy. CPDA‐based core‐shell nanoparticles (CPDANP) are engineered for drug Dox release in the tumor microenvironment using boronate ester links between polymeric chains of CPDANP and imine linkages for conjugating Dox to CPDANP (CPDANP‐Dox). The nanoparticles are characterized for their size, effective charge, and core‐shell like structure by DLS and TEM and radiolabeled with 125 I. Gal‐3 specific targeting of CPDANP‐Dox and 125 I to the nucleus of tumor cells is confirmed by fluorescence microscopy and estimating radioactivity in the isolated nucleus of cells. In vitro and in vivo studies demonstrated that the combination therapy with [ 125 I] I‐CPDANP‐Dox exhibited enhanced cytotoxicity in TNBC cells. SPECT imaging and biodistribution studies showed rapid clearance of the formulations from the bloodstream, and tumor regression studies in 4T1 tumor‐bearing mice confirmed the therapeutic superiority of the combined treatment over individual therapies. This study highlights the potential of CPDANP as a dual‐targeting platform for efficient Auger‐chemo therapy in the treatment of TNBC.


  • Open Access

    Unravelling the Antimicrobial Action Mechanism of Ribosomal Protein S30

    by J. Bhatt Mitra, V. K. Sharma, M. Kumar, V. Garcia Sakai, A. Mukherjee

    Ribosomal protein S30 (RS30) exhibits potent antimicrobial activity against a broad spectrum of bacteria. Despite its efficacy, the underlying action mechanism remained elusive. In this study, we unravel the fundamental mechanism by which RS30 exerts its bactericidal effects, using a combination of microbiological assays and advanced biophysical techniques. Microbiological analyses reveal that RS30 kills bacteria primarily through membrane depolarization, despite limited membrane permeabilization, indicating an unconventional mode of action involving no or partial lysis of the membrane. Importantly, RS30 demonstrates time-dependent bactericidal activity with no detectable cytotoxicity toward mammalian cells, underscoring its high selectivity. This selective action was further confirmed using biophysical experiments on model membrane systems composed of anionic (bacterial mimic) and zwitterionic (mammalian mimic) phospholipids. Our measurements suggested that RS30 preferentially binds to anionic membranes via electrostatic interactions, undergoes a conformational transition from a random coil to an α-helix upon binding, and induces vesicle aggregation. Quasielastic neutron scattering (QENS) measurements provide microscopic insights, showing that RS30 significantly restricts the lateral diffusion of anionic lipids, thereby perturbing membrane dynamics and increasing susceptibility to external stress. Together, our findings uncover important insights into the antimicrobial action mechanism of RS30, characterized by selective membrane interaction, structural transformation, and dynamic modulation of lipid membranes.